Breaking News
September 25, 2018 - New program to reduce harmful stress effectively improves mood in cancer patients
September 24, 2018 - Florence’s Lingering Threat: Mold – Drugs.com MedNews
September 24, 2018 - For professional baseball players, faster hand-eye coordination linked to batting performance
September 24, 2018 - Bill for later school start times is defeated, but Stanford sleep specialist isn’t
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Successful recovery from addiction means more than achieving abstinence
September 24, 2018 - New nanoplatform technology may reverse drug-resistance in renal cell carcinoma
September 24, 2018 - October 1918 marks the centenary of Spanish Flu that claimed more lives than World War I
September 24, 2018 - LGBT community reports more number of poor mental health days than general population
September 24, 2018 - New research suggests power of zebrafish as tool for cancer drug discovery
September 24, 2018 - New study finds height as possible risk factor for developing varicose veins
September 24, 2018 - Researchers compare weight loss results of online and in-person diabetes prevention program
September 24, 2018 - New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment
September 24, 2018 - Drug combination offers more effective care for patients suffering miscarriage
September 24, 2018 - Tallness linked to varicose veins, Stanford study says
September 24, 2018 - For Heart Failure Patients, Mitral Valve Procedure Improved Outcomes
September 24, 2018 - Ecstasy drug makes octopuses more social
September 24, 2018 - Immediate compression therapy could cut risk of complications after deep-vein thrombosis
September 24, 2018 - Transcatheter mitral valve repair reduces mortality for patients with mitral regurgitation
September 24, 2018 - First intracranial aneurysm patients treated with BRAVO Flow Diverter after CE mark approval
September 24, 2018 - ‘Physicians of the mouth’? Dentists absorb the medical billing drill
September 24, 2018 - People more likely to believe those with confident tone of voice than with accent
September 24, 2018 - Harmony Biosciences Presents 5-Year Data On Pitolisant At International Narcolepsy Symposium
September 24, 2018 - Blood test may identify gestational diabetes risk in first trimester
September 24, 2018 - Height may be risk factor for varicose veins | News Center
September 24, 2018 - King’s commemorates opening of new NMR facility with one-day symposium
September 24, 2018 - Eisai receives approval for partial label change of DC Bead device for transcatheter arterial embolization
September 24, 2018 - High-resolution genomic map gives scientists unprecedented view of brain development
September 24, 2018 - Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD
September 24, 2018 - First evaluation of benefits, harms of Alzheimer’s screening for family members of older adults
September 24, 2018 - Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System
September 24, 2018 - Children of mothers using cannabis may start using it at an earlier age, finds study
September 24, 2018 - Gilead Sciences plans to launch authorized generic versions of Epclusa and Harvoni in the US
September 24, 2018 - Most patients who underwent transcatheter valve replacement experience prosthesis-patient mismatch
September 24, 2018 - Lumos acquires license for LUM-201 drug that promotes secretion of growth hormone
September 24, 2018 - New study provides basis for Air Canada to change its facial hair policy for aircrew
September 24, 2018 - Infant walkers lead to thousands of emergency visits for babies
September 24, 2018 - Genes predicting person’s height may provide clues about causes of varicose veins
September 24, 2018 - EPA Plan Will Maintain Carbon Emissions From Power Plants
September 24, 2018 - Characterizing pig hippocampus could improve translational neuroscience
September 24, 2018 - Element3 Health reports social and mental engagement play key role in overall health
September 24, 2018 - Paralympic medalists support Fight for Sight’s unique virtual event
September 24, 2018 - ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma
September 24, 2018 - Public awareness of urological conditions found to be alarmingly low across Europe
September 24, 2018 - Fitter Folks Suffer Milder Strokes: Study
September 24, 2018 - Novel botulinum toxin compound relieves chronic pain
September 24, 2018 - CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents
September 24, 2018 - National Friendly’s private medical insurance is a hit with women living in the South East
September 24, 2018 - Academics receive prestigious awards for achievements in blood pressure research
September 24, 2018 - Obese pregnant women can restrict weight gain safely with proper nutrition guidance
September 24, 2018 - CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer
September 24, 2018 - China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma
September 24, 2018 - A new approach for finding Alzheimer’s treatments
September 24, 2018 - USC research uncovers previously unknown genetic risk factor for dementia
September 24, 2018 - Study examining mental health among students finds significant disparities in treatment across race
September 24, 2018 - Breakthrough discovery paves way for future test to identify drowsy drivers
September 24, 2018 - Transcatheter mitral-valve repair in patients with heart failure
September 24, 2018 - Study opens new avenues for treatment of Laing distal myopathy
September 24, 2018 - Stroke Facts | cdc.gov
September 24, 2018 - Sarcolipin tricks muscle cells into using more energy, burning fat
September 24, 2018 - Enrollment in opioid controlled substance agreement reduces primary care visits
September 24, 2018 - UTA researchers patent new smart seat cushion technology that helps prevent painful ulcers
September 24, 2018 - Second HPV-Related Primary Cancers Common in Survivors
September 24, 2018 - How a virus destabilizes the genome
September 24, 2018 - Old letters provide insight into Spanish flu pandemic horror
September 23, 2018 - Smart textile-based soft robotic exosuit helps wearers save energy and traverse difficult terrain
September 23, 2018 - New research hub to drive radical change in development and manufacturing of vaccines
September 23, 2018 - AHA: For Hispanics, Neighborhood May Be Key Factor in Heart Disease Risk
September 23, 2018 - Excessive airway nerves tied to more severe asthma symptoms, study finds
September 23, 2018 - Study highlights need to remain vigilant in maintaining key infection control processes
September 23, 2018 - Novel therapeutic strategy for blood vessel related disorders, such as cancer and retinopathy
September 23, 2018 - New naturally occurring antibiotic found effective against Mycobacterium tuberculosis
September 23, 2018 - First-in-human phase 0 study shows clinically-relevant activity of new drug in glioblastoma
September 23, 2018 - Removing tobacco product display from shops reduced number of children buying cigarettes
September 23, 2018 - Random fraction of specialized immune cells leads the charge in battling invaders
September 23, 2018 - Few minutes of sprinting exercise may be as effective as longer exercise sessions
September 23, 2018 - Researchers use neutrons to make first direct observations of water in lipid bilayers
September 23, 2018 - Researchers demonstrate pre-clinical success for universal flu vaccine in new paper
September 23, 2018 - Study reveals surprising gaps in some HIV medical providers’ knowledge of ACA
September 23, 2018 - Oxehealth secures European medical device accreditation for vital signs measurement software
Takeda declares speeded up approval from FDA for brand new lung most cancers remedy

Takeda declares speeded up approval from FDA for brand new lung most cancers remedy

image_pdfDownload PDFimage_print

Takeda Pharmaceutical Corporate Restricted (TSE: 4502) nowadays introduced that ALUNBRIG™ (brigatinib) has gained Speeded up Approval from the U.S. Meals and Drug Management (FDA) for the remedy of sufferers with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cellular lung most cancers (NSCLC) who’ve advanced on or are illiberal to crizotinib. This indication is licensed underneath Speeded up Approval according to tumor reaction charge and length of reaction. Persisted acclaim for this indication could also be contingent upon verification and outline of scientific get advantages in a confirmatory trial. ALUNBRIG, which in the past gained Step forward Remedy Designation from the FDA, is a once-daily oral remedy that can be taken without or with meals.

“Lately, small molecule ALK inhibitors have revolutionized the remedy choices for the ones with complicated ALK+ non-small cellular lung most cancers. However, there may be nonetheless a necessity for extra ALK inhibitors like brigatinib (ALUNBRIG), that have a manageable protection profile and might deal with mechanisms of scientific resistance to crizotinib, together with development within the central apprehensive machine,” mentioned D. Ross Camidge, M.D., Ph.D., director of thoracic oncology on the College of Colorado. “The ALTA trial confirmed that brigatinib (ALUNBRIG) used to be extremely efficient post-crizotinib with the vast majority of sufferers who gained 180 mg as soon as on daily basis with a seven-day lead in at 90 mg as soon as on daily basis attaining an total reaction and a mean length of reaction more than 365 days. Importantly, the level of task amongst the ones with mind metastases used to be additionally notable.”

“For sufferers with ALK+ metastatic NSCLC who’ve advanced on or are illiberal to crizotinib, who’re going through the uncertainty of illness development and the doubtless devastating have an effect on of mind metastases, the approval of ALUNBRIG gives a brand new hope,” mentioned Bonnie Addario, founder and chair of the Addario Lung Most cancers Basis (ALCF).

“The fast construction of ALUNBRIG is a tribute to the determination of many analysis scientists and clinicians who sparsely designed and evolved this new medication to deal with unmet clinical wishes within the ALK+ NSCLC affected person inhabitants. Most significantly, we wish to thank the sufferers and households who participated within the scientific trials,” mentioned Andy Plump, M.D., Ph.D., Takeda Leader Scientific and Clinical Officer.

“Nowadays’s FDA approval of ALUNBRIG is crucial milestone within the remedy of sufferers with ALK+ metastatic NSCLC who’ve advanced on or are illiberal to crizotinib,” mentioned Christophe Bianchi, M.D., President, Takeda Oncology. “Takeda is dedicated to the ongoing construction of ALUNBRIG all over the world and to bringing this essential remedy to extra sufferers in want.”

In regards to the ALTA Trial

The FDA approval of ALUNBRIG used to be essentially according to effects from the pivotal Segment 2 ALTA (ALK in Lung Most cancers Trial of AP26113) trial of brigatinib in adults. This ongoing, two-arm, open-label, multicenter trial enrolled 222 sufferers with in the neighborhood complicated or metastatic ALK+ NSCLC who had advanced on crizotinib. Sufferers gained both 90 mg of ALUNBRIG as soon as on daily basis (n=112) or 180 mg as soon as on daily basis following a seven-day lead-in of 90 mg as soon as on daily basis (n=110). The foremost efficacy end result measure used to be showed total reaction charge (ORR) in step with Reaction Analysis Standards in Forged Tumors (RECIST v1.1) as evaluated through an Unbiased Evaluation Committee (IRC). Further efficacy end result measures integrated Investigator-assessed ORR, length of reaction (DOR), intracranial ORR, and intracranial DOR.

The really helpful dosing routine for ALUNBRIG is 90 mg orally as soon as on daily basis for the primary 7 days. If 90 mg is tolerated right through the primary 7 days, building up the dose to 180 mg orally as soon as on daily basis.

With a mean follow-up of eight months (vary zero.1 – 20.2), effects demonstrated that of the sufferers who gained the really helpful dosing routine (90→180 mg), 53 % completed a showed total reaction (OR) as assessed through IRC and 54 % as assessed through Investigator. On the really helpful dosing routine, the median length of reaction used to be 13.eight months as assessed through IRC and 11.1 months through Investigator review. Moreover, on the really helpful dosing routine, 67 % of sufferers with measurable mind metastases (n=18) completed a showed intracranial OR through IRC review.

Efficacy information are as follows:

CI = Self assurance Period; NE = Now not Estimable

IRC review of intracranial efficacy is proven beneath:

CI = Self assurance Period; NE = Now not Estimable

A few of the 23 sufferers who exhibited an intracranial reaction, 78% of sufferers within the 90 mg arm and 68% of sufferers within the 90→180 mg team maintained a reaction for no less than 4 months.

The warnings and precautions for ALUNBRIG are: interstitial lung illness (ILD)/pneumonitis, high blood pressure, bradycardia, visible disturbance, creatine phosphokinase (CPK) elevation, pancreatic enzyme elevation, hyperglycemia and embryo-fetal toxicity.

Critical hostile reactions befell in 38% of sufferers within the 90 mg team and 40% of sufferers within the 90→180 mg team. The most typical severe hostile reactions have been pneumonia (five.five% total, Three.7% within the 90 mg team, and seven.Three% within the 90→180 mg team) and ILD/pneumonitis (Four.6% total, 1.eight% within the 90 mg team and seven.Three% within the 90→180 mg team). Deadly hostile reactions befell in Three.7% of sufferers and consisted of pneumonia (2 sufferers), surprising dying, dyspnea, respiration failure, pulmonary embolism, bacterial meningitis and urosepsis (1 affected person each and every).

On the really helpful dosing routine, the most typical hostile reactions (≥25%) with ALUNBRIG have been nausea, diarrhea, fatigue, cough, and headache.

About ALK+ NSCLC

Non-small cellular lung most cancers (NSCLC) is the most typical type of lung most cancers, accounting for about 85 % of the estimated 222,500 new circumstances of lung most cancers recognized each and every 12 months in the USA, in step with the American Most cancers Society. Genetic research point out that chromosomal rearrangements in anaplastic lymphoma kinase (ALK) are key drivers in a subset of NSCLC sufferers as neatly. Roughly two to 8 % of sufferers with NSCLC have a rearrangement within the ALK gene.

The central apprehensive machine (CNS) is a common website for ALK+ NSCLC development, with as much as 70 % of sufferers with ALK+ NSCLC who’ve been handled with a first-line ALK inhibitor going through mind metastases.

About ALUNBRIG™ (brigatinib)

ALUNBRIG is a centered most cancers medication found out through ARIAD Prescription drugs, Inc., which used to be received through Takeda in February 2017. ALUNBRIG gained Step forward Remedy Designation from the FDA for the remedy of sufferers with ALK+ NSCLC whose tumors are proof against crizotinib, and used to be granted Orphan Drug Designation through the FDA for the remedy of ALK+ NSCLC, ROS1+ and EGFR+ NSCLC. A Advertising and marketing Authorization Software (MAA) for ALUNBRIG used to be submitted to the Ecu Medications Company (EMA) in February 2017.

The ALTA scientific construction program additional reinforces Takeda’s ongoing dedication to growing cutting edge remedies for folks residing with ALK+ NSCLC international and the healthcare execs who deal with them. Along with the continuing Segment half and Segment 2 ALTA trial, brigatinib could also be being studied within the Segment Three ALTA 1L trial to evaluate its efficacy and protection compared to crizotinib in sufferers with in the neighborhood complicated or metastatic ALK+ NSCLC who’ve no longer gained prior remedy with an ALK inhibitor.

To be informed extra about ALUNBRIG, please talk over with www.ALUNBRIG.com or name A1Point: 1-844-A1POINT (1-844-217-6468).

For more information at the brigatinib scientific trials, please talk over with www.clinicaltrials.gov.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS
Interstitial Lung Illness (ILD)/Pneumonitis: Critical, life-threatening, and deadly pulmonary hostile reactions in step with interstitial lung illness (ILD)/pneumonitis have befell with ALUNBRIG. In Trial ALTA (ALTA), ILD/pneumonitis befell in Three.7% of sufferers within the 90 mg team (90 mg as soon as on daily basis) and nine.1% of sufferers within the 90→180 mg team (180 mg as soon as on daily basis with 7-day lead-in at 90 mg as soon as on daily basis). Adversarial reactions in step with imaginable ILD/pneumonitis befell early (inside of nine days of initiation of ALUNBRIG; median onset used to be 2 days) in 6.Four% of sufferers, with Grade Three to Four reactions happening in 2.7%. Observe for brand new or worsening respiration signs (e.g., dyspnea, cough, and so on.), in particular right through the primary week of starting up ALUNBRIG. Withhold ALUNBRIG in any affected person with new or worsening respiration signs, and promptly overview for ILD/pneumonitis or different reasons of respiration signs (e.g., pulmonary embolism, tumor development, and infectious pneumonia). For Grade 1 or 2 ILD/pneumonitis, both resume ALUNBRIG with dose relief after restoration to baseline or completely discontinue ALUNBRIG. Completely discontinue ALUNBRIG for Grade Three or Four ILD/pneumonitis or recurrence of Grade 1 or 2 ILD/pneumonitis.

High blood pressure: In ALTA, high blood pressure used to be reported in 11% of sufferers within the 90 mg team who gained ALUNBRIG and 21% of sufferers within the 90→180 mg team. Grade Three high blood pressure befell in five.nine% of sufferers total. Regulate blood force previous to remedy with ALUNBRIG. Observe blood force after 2 weeks and no less than per month thereafter right through remedy with ALUNBRIG. Withhold ALUNBRIG for Grade Three high blood pressure regardless of optimum antihypertensive remedy. Upon solution or growth to Grade 1 severity, resume ALUNBRIG at a discounted dose. Imagine everlasting discontinuation of remedy with ALUNBRIG for Grade Four high blood pressure or recurrence of Grade Three high blood pressure. Use warning when administering ALUNBRIG together with antihypertensive brokers that reason bradycardia.

Bradycardia: Bradycardia can happen with ALUNBRIG. In ALTA, middle charges not up to 50 beats consistent with minute (bpm) befell in five.7% of sufferers within the 90 mg team and seven.6% of sufferers within the 90→180 mg team. Grade 2 bradycardia befell in 1 (zero.nine%) affected person within the 90 mg team. Observe middle charge and blood force right through remedy with ALUNBRIG. Observe sufferers extra regularly if concomitant use of drug recognized to reason bradycardia can’t be have shyed away from. For symptomatic bradycardia, withhold ALUNBRIG and assessment concomitant drugs for the ones recognized to reason bradycardia. If a concomitant medicine recognized to reason bradycardia is known and discontinued or dose adjusted, resume ALUNBRIG on the identical dose following solution of symptomatic bradycardia; in a different way, cut back the dose of ALUNBRIG following solution of symptomatic bradycardia. Discontinue ALUNBRIG for life-threatening bradycardia if no contributing concomitant medicine is known.

Visible Disturbance: In ALTA, hostile reactions resulting in visible disturbance together with blurred imaginative and prescient, diplopia, and decreased visible acuity, have been reported in 7.Three% of sufferers handled with ALUNBRIG within the 90 mg team and 10% of sufferers within the 90→180 mg team. Grade Three macular edema and cataract befell in a single affected person each and every within the 90→180 mg team. Advise sufferers to file any visible signs. Withhold ALUNBRIG and acquire an ophthalmologic analysis in sufferers with new or worsening visible signs of Grade 2 or larger severity. Upon restoration of Grade 2 or Grade Three visible disturbances to Grade 1 severity or baseline, resume ALUNBRIG at a discounted dose. Completely discontinue remedy with ALUNBRIG for Grade Four visible disturbances.

Creatine Phosphokinase (CPK) Elevation: In ALTA, creatine phosphokinase (CPK) elevation befell in 27% of sufferers receiving ALUNBRIG within the 90 mg team and 48% of sufferers within the 90 mg→180 mg team. The occurrence of Grade Three-Four CPK elevation used to be 2.eight% within the 90 mg team and 12% within the 90→180 mg team. Dose relief for CPK elevation befell in 1.eight% of sufferers within the 90 mg team and four.five% within the 90→180 mg team. Advise sufferers to file any unexplained muscle ache, tenderness, or weak point. Observe CPK ranges right through ALUNBRIG remedy. Withhold ALUNBRIG for Grade Three or Four CPK elevation. Upon solution or restoration to Grade 1 or baseline, resume ALUNBRIG on the identical dose or at a discounted dose.

Pancreatic Enzyme Elevation: In ALTA, amylase elevation befell in 27% of sufferers within the 90 mg team and 39% of sufferers within the 90→180 mg team. Lipase elevations befell in 21% of sufferers within the 90 mg team and 45% of sufferers within the 90→180 mg team. Grade Three or Four amylase elevation befell in Three.7% of sufferers within the 90 mg team and a couple of.7% of sufferers within the 90→180 mg team. Grade Three or Four lipase elevation befell in Four.6% of sufferers within the 90 mg team and five.five% of sufferers within the 90→180 mg team. Observe lipase and amylase right through remedy with ALUNBRIG. Withhold ALUNBRIG for Grade Three or Four pancreatic enzyme elevation. Upon solution or restoration to Grade 1 or baseline, resume ALUNBRIG on the identical dose or at a discounted dose.

Hyperglycemia: In ALTA, 43% of sufferers who gained ALUNBRIG skilled new or worsening hyperglycemia. Grade Three hyperglycemia, according to laboratory review of serum fasting glucose ranges, befell in Three.7% of sufferers. Two of 20 (10%) sufferers with diabetes or glucose intolerance at baseline required initiation of insulin whilst receiving ALUNBRIG. Assess fasting serum glucose previous to initiation of ALUNBRIG and track periodically thereafter. Start up or optimize anti-hyperglycemic drugs as wanted. If good enough hyperglycemic regulate can’t be completed with optimum clinical control, withhold ALUNBRIG till good enough hyperglycemic regulate is completed and believe lowering the dose of ALUNBRIG or completely discontinuing ALUNBRIG.

Embryo-Fetal Toxicity: In line with its mechanism of motion and findings in animals, ALUNBRIG could cause fetal hurt when administered to pregnant girls. There are not any scientific information on using ALUNBRIG in pregnant girls. Advise pregnant girls of the possible possibility to a fetus. Advise women folk of reproductive attainable to make use of efficient non-hormonal birth control right through remedy with ALUNBRIG and for no less than Four months following the overall dose. Advise men with feminine companions of reproductive attainable to make use of efficient birth control right through remedy and for no less than Three months after the closing dose of ALUNBRIG.

ADVERSE REACTIONS
Critical hostile reactions befell in 38% of sufferers within the 90 mg team and 40% of sufferers within the 90→180 mg team. The most typical severe hostile reactions have been pneumonia (five.five% total, Three.7% within the 90 mg team, and seven.Three% within the 90→180 mg team) and ILD/pneumonitis (Four.6% total, 1.eight% within the 90 mg team and seven.Three% within the 90→180 mg team). Deadly hostile reactions befell in Three.7% of sufferers and consisted of pneumonia (2 sufferers), surprising dying, dyspnea, respiration failure, pulmonary embolism, bacterial meningitis and urosepsis (1 affected person each and every).

The most typical hostile reactions (≥25%) within the 90 mg team have been nausea (33%), fatigue (29%), headache (28%), and dyspnea (27%) and within the 90→180 mg team have been nausea (40%), diarrhea (38%), fatigue (36%), cough (34%), and headache (27%).

DRUG INTERACTIONS
CYP3A Inhibitors: Keep away from concomitant use of ALUNBRIG with robust CYP3A inhibitors. Keep away from grapefruit or grapefruit juice because it may additionally building up plasma concentrations of brigatinib. If concomitant use of a robust CYP3A inhibitor is unavoidable, cut back the dose of ALUNBRIG.
CYP3A Inducers: Keep away from concomitant use of ALUNBRIG with robust CYP3A inducers.
CYP3A Substrates: Coadministration of ALUNBRIG with CYP3A substrates, together with hormonal contraceptives, can lead to reduced concentrations and lack of efficacy of CYP3A substrates.

USE IN SPECIFIC POPULATIONS
Being pregnant: ALUNBRIG could cause fetal hurt. Advise women folk of reproductive attainable of the possible possibility to a fetus.
Lactation: Advise lactating girls to not breastfeed right through remedy with ALUNBRIG and for 1 week following the overall dose.
Ladies and Men of Reproductive Attainable:
Birth control: Advise women folk of reproductive attainable to make use of efficient non-hormonal birth control right through remedy with ALUNBRIG and for no less than Four months after the overall dose. Advise men with feminine companions of reproductive attainable to make use of efficient birth control right through remedy with ALUNBRIG and for no less than Three months after the overall dose.
Infertility: ALUNBRIG might reason decreased fertility in men.
Pediatric Use: The protection and efficacy of ALUNBRIG in pediatric sufferers have no longer been established.
Geriatric Use: Medical research of ALUNBRIG didn’t come with enough numbers of sufferers elderly 65 years and older to resolve whether or not they reply in a different way from more youthful sufferers. Of the 222 sufferers in ALTA, 19.Four% have been 65-74 years and four.1% have been 75 years or older. No clinically related variations in protection or efficacy have been seen between sufferers ≥65 and more youthful sufferers.
Hepatic or Renal Impairment: No dose adjustment is really helpful for sufferers with gentle hepatic impairment or gentle or average renal impairment. The protection of ALUNBRIG in sufferers with average or serious hepatic impairment or serious renal impairment has no longer been studied.

Supply:

https://www.takeda.com/newsroom/newsreleases/2017/alunbrig-fda-approval/

Tagged with:

About author

Related Articles